


SAFETY AND EFFECTIVENESS IN REDUCED DOSE OF OMALIZUMAB FOR CHRONIC IDIOPATHIC URTICARIA

M. ALONSO MORENO¹, M. SORIANO MARTINEZ¹, B. FERNANDEZ RUBIO¹, M. MEJIAS TRUEBA¹.
¹HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO, PHARMACY, SEVILLE, SPAIN

BACKGROUND AND IMPORTANCE



MATERIAL AND METHODS

Observational, descriptive and retrospective study of omalizumab prescribed for adult patients in CIU from January 2015 to September 2019 in a third level hospital.

Variables collected: sex, age, service (allergy or dermatology), previous treatments, initiating dosing, dose change, clinical variable Urticaria Activity Score 7 (UAS7), suspension of treatment and adverse events (AE)

AIM AND OBJECTIVES

safety and effectiveness of omalizumab in both doses for the treatment of CIU


RESULTS

67.31% women
median age of 50.5 years

65.38% allergy
34.62% dermatology

N=52

All patients previously received antihistamines, montelukast and cyclosporine.



□ UAS7 before treatment: 29.5 (range: 20-42)
□ UAS7 during treatment: 0 (range: 0-32)
with both doses of omalizumab

AE → n=2 alopecia and asthenia; and weight gain

CONCLUSIONS AND RELEVANCE

There is a high percentage of patients in our center with a dose of 300 mg monthly of omalizumab for CIU, however a reduced dose (150mg monthly) has also proved to be equally effective and safe, even stopping the treatment for improvement of CIU which would be also economic impact.

